These three drugs have been shown to be ineffective in treating COVID-19
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
These three drugs have been shown to be ineffective in treating COVID-19
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
These three drugs have been shown to be ineffective in treating COVID-19.In the face of the sudden outbreak of COVID-19, the new use of old drugs has become the main way to find treatment options for COVID-19.
Through rigorous clinical research design: randomized, double-blind, placebo-controlled large-sample multi-center clinical trials, medical scientists have found a series of old drugs that reduce the mortality rate of severe COVID-19 patients, the most typical of which is dexamethasone, which is cheap Another easy-to-obtain old drug: the clinical trial results are released at noon, and the UK will be promoted nationwide in the afternoon.
However, more older medicines have proven ineffective for quality COVID-19.
On August 18, 2022, the COVID-OUT clinical research group led by the University of Minnesota reported in the New England Journal of Medicine (NEJM) the results of a large-scale clinical trial of the new use of old drugs to treat COVID-19 [1].
This large randomized placebo-controlled Phase 3 clinical trial (NCT04510194) evaluated 3 of the frequently discussed drugs: metformin, ivermectin and fluvoxamine. 1323 patients with COVID-19 shortly after diagnosis were enrolled, with a median age of 46 years and 56% women. 52% were vaccinated.
The study found that compared with the control group, the adjusted risk factors for disease progression after metformin use aOR=0.84, p=0.19; ivermectin aOR=1.05, p=0.78; fluvoxamine aOR=0.94, p=0.75. None of the three drugs had a significant benefit in improving patient symptoms and clinical manifestations.
The study further found that there was no significant reduction in hospitalization and death among patients receiving the three drugs, aOR=0.47; ivermectin aOR=0.73; fluvoxamine aOR=1.11.
Summary:
The study found that none of the three drugs , metformin, ivermectin, and fluvoxamine, improved symptoms early at diagnosis, nor did they reduce hospitalizations and deaths.
For a new disease such as COVID-19, doctors can only diagnose and treat based on the consensus formed by the best evidence currently available at the beginning; then adjust or improve it when new evidence is available.
In the process of repeated verification, especially relying on the results of RCT research, medicine has been advanced; finally, empirical medicine has been transformed into evidence-based medicine.
Related news:
NEJM: Metformin can effectively reduce the risk of severe COVID-19
References:
[ 1] https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.